Overexpression of the receptor tyrosine kinase ERBB2 (also known as HER2) occurs in around 15% of breast cancers and is driven by amplification of the ERBB2 gene. ERBB2 amplification is a marker of poor prognosis, and although anti-ERBB2-targeted therapies have shown significant clinical benefit, de novo and acquired resistance remains an important problem. Genomic profiling has demonstrated that ERBB2 þ ve breast cancers are distinguished from ER þ ve and 'triple-negative' breast cancers by harbouring not only the ERBB2 amplification on 17q12, but also a number of co-amplified genes on 17q12 and amplification events on other chromosomes. Some of these genes may have important roles in influencing clinical outcome, and could represent genetic dependencies in ERBB2 þ ve cancers and therefore potential therapeutic targets. Here, we describe an integrated genomic, gene expression and functional analysis to determine whether the genes present within amplicons are critical for the survival of ERBB2 þ ve breast tumour cells. We show that only a fraction of the ERBB2-amplified breast tumour lines are truly addicted to the ERBB2 oncogene at the mRNA level and display a heterogeneous set of additional genetic dependencies. These include an addiction to the transcription factor gene TFAP2C when it is amplified and overexpressed, suggesting that TFAP2C represents a genetic dependency in some ERBB2 þ ve breast cancer cells.
INTRODUCTION
Amplification and overexpression of the gene encoding the receptor tyrosine kinase ERBB2 is present in around 15% of all breast cancers, and is associated with aggressive disease and poor clinical outcome. Anti-ERBB2-targeted therapies such as trastuzumab and lapatinib have been shown to significantly increase the survival of patients with ERBB2 þ ve cancer, 1,2 but de novo resistance is common with response rates of B30% in the metastatic setting. 3 Therefore, the positive predictive value of ERBB2 amplification/ overexpression for trastuzumab sensitivity is relatively low. Furthermore, acquired resistance to trastuzumab inevitably occurs in the metastatic setting as represented by a progression-free survival benefit of only 2.2 months when compared with standard chemotherapy. 1 In the adjuvant setting, relapse-free survival is significantly prolonged with trastuzumab-chemotherapy combinations, 4, 5 although overall survival benefits may be somewhat lower than first hoped 6, 7 Therefore, the identification of additional drivers of ERBB2 þ ve cancer is required, and better prognostic and predictive biomarkers are needed.
At the genomic level, ERBB2-amplified breast cancers display complex genome profiles and a number of discrete gene amplification events. For example, amplifications of genetic material at chromosomes 1q, 8q, 17q and 20q are relatively common events in ERBB2-amplified breast tumours. [8] [9] [10] However, with the exception of ERBB2 itself, the biological significance of these additional amplification events is not yet clear. Some of these amplicons most likely encompass bona fide oncogenes and candidate therapeutic targets. 11, 12 Here, we describe an integrated genetic, transcriptomic and functional analysis of a wide panel of genes amplified and overexpressed in ERBB2 þ ve breast tumours and the identification of additional genetic dependencies in ERBB2 þ ve breast cancer models.
RESULTS

ERBB2-amplified breast cancers are heterogeneous at the genomic level
To investigate the significance of amplification events in ERBB2 þ ve breast cancer we used an integrated approach. In summary, this involved (i) generating genomic and transcriptomic profiles of a well-curated panel of primary breast cancers harbouring ERBB2 gene amplification; (ii) integrating these data to identify effects where gene amplification corresponded with high-level expression of the same gene; and (iii) the use of high throughput RNA interference screening to functionally assess whether genes that are amplified and overexpressed are also essential for tumour cell survival. To analyse the genomic composition of ERBB2 þ ve breast tumours, we used a high-resolution Array-based Comparative Genome Hybridization (aCGH) platform. This platform has a resolution of 50 kb and has previously been used to identify subsequently validated gene copy number aberrations in other human tumours. [13] [14] [15] Using this platform, we profiled DNA extracted from 58 primary, fresh frozen, ERBB2-amplified breast cancers. To minimise the confounding effects of stromal material, 16 all tumours were either determined by light microscopy to contain over 70% tumour content or microdissected to remove stromal contamination, ensuring at least 70% of tumour cell content in the final dissected material. The main clinicopathological characteristics of these tumours are described in Supplementary Table S1. All tumours were from patients who had not received neoadjuvant therapy. ERBB2 overexpression in each tumour had been previously defined by immunohistochemistry (3 þ ) and ERBB2 amplification confirmed by chromogenic in situ hybridization (CISH) and/or aCGH to a 381 kb smallest region of amplification on 17q12; 34.98-35.36 Mb (Supplementary Figure 1) .
The majority of tumours exhibited a 'firestorm' genomic pattern 17 characterized by multiple discrete amplifications (Figure 1ai , data available on the ROCK database 18 (www.rock. icr.ac.uk)), supporting previous observations. 10, 19 We also noted a small number of tumours (7/58, 12%) that displayed a 'sawtooth' pattern 17 (Figure 1aii ), which is reported to be more commonly associated with basal-like/triple-negative breast cancers. 20 The number of amplifications seen in each tumour was variable (mean ¼ 13 s.d. þ / À 6.6, range 1-34). In total, 122 discrete and recurrent loci (nX2) of high-level gains and/or amplicons were identified (Figure 1bi) . Consistent with previous studies, 10, 19 the most prevalent regions of amplification included 8q24 (8.8% of all tumours), 11q13 (11%) and 20q13 (13%). In our analysis we also noted moderate differences between the ERBB2 þ /ER þ and ERBB2 þ /ER À tumour subgroups. Although only 0.87% of the genome was differentially gained, lost or amplified, loss of 14q32.2 was significantly more prevalent (Po0.05 Fisher's exact test adjusted for multiple comparisons in the ERBB2 þ /ER À subgroup when compared with the ERBB2 þ /ER þ subgroup. Amplification of 17q12 (Start; End 32.82:33.21 Mb) was significantly more prevalent in ERBB2 þ /ER þ ve tumours (Po0.05) as shown in Supplementary Table S2 .
This genomic profiling confirmed previous suggestions 10, 19 that, rather than being homogeneous at the genomic level, ERBB2-amplified breast tumours exhibit a significant level of genomic heterogeneity, though not greatly influenced by oestrogen i i i aCGH log ratio aCGH log ratio Chromosome  Chromosome   X  20  18  16  14  12  10  9  8  7  6  5  4  3  2  1  X  20  18  16  14  12  10  9  8  7  6  5 receptor (ER) status, perhaps explaining the variable clinical behaviour of ERBB2 þ ve disease.
Integration of genomic and transcriptomic data from ERBB2-amplified tumours On the basis of the ERBB2 paradigm, where gene addiction effects may be represented by gene amplification that drives high-level expression, our aim was to identify similar 'driver' genes within the multiple amplicons we had identified. 21 RNA of sufficient quality was available from most (76%, 45/58) of the tumours, which we had genomically characterized and so these were profiled using gene expression microarrays as previously described. 14, 22 We used two parallel methods to select genes within amplicons to functionally validate: (i) a Pearson's correlation to determine the genes whose expression was significantly associated with changes in gene copy number and (ii) a Mann-Whitney U-test to assess correlation between transcript levels and amplification status as previously described. 23 Genes identified as having significant correlation between copy number/amplification and expression using either statistical method totalled 511 (Figures 2a and b and Supplementary Table S3 ). In the 45 tumours, 93 unique recurrent (nX2) amplicons were identified (Figure 2c ). The majority of genes (323, 63%) were identified using both methods included MTDH, PPM1D, RPS6KB1 and AURKA. The oncogenic nature of many of these genes has been previously demonstrated, 13, 24, 25 suggesting that using this approach may constitute a valid approach for the identification of additional candidate drivers in ERBB2-amplified tumours. A total of 168 genes exclusively identified using Pearson's correlation (168, 33%) included ERBB2, GRB7 and STARD3 on the ERBB2 amplicon, and MYC and ZNF217 on 8q24 and 20q13, respectively. An additional 20 genes (4%) were exclusively identified using the Mann-Whitney U-test and included CCND1, RAB34 and ORAOV2.
Genomic and transcriptomic profiling of an ERBB2-amplified breast tumour cell line panel We aimed to identify amplified and overexpressed genes in ERBB2-amplified tumours and functionally assess the possibility that these same genes were also essential for tumour cell survival and, therefore, be candidate therapeutic targets. To define suitable models for high throughput short interfering RNA (siRNA) screening, we compiled a panel of 14 ERBB2-amplified and 9 non-ERBB2-amplified breast cancer cell lines and characterized this panel by aCGH and expression arrays in a similar fashion to the tumour collection. 18 As observed in the tumours, the 14 ERBB2-amplified cell lines exhibited multiple recurrent amplifications (n ¼ 67), although common amplicons on 1q, 8q, 11q, 17q and 20q were again noted ( Figure 1bii ) and all displayed a 'firestorm' pattern. In addition, the ERBB2, ER and progesterone receptor status of these cell lines was defined by CISH and immunohistochemistry on a customised cell line microarray (Figures 3a-c) . Finally, we also used viability profiling to define the sensitivity of each cell line to the small molecule ERBB2 inhibitor, lapatinib (Figure 3d ).
Functional profiling in ERBB2-amplified breast tumour models Analysis of the aCGH and expression profiles of tumour cell lines suggested that 72% (369/511) of the amplified/overexpressed genes identified in the primary tumour analysis were also amplified in at least two cell lines (Figure 2c and Supplementary  Table S3 ). To establish the functional significance of amplified/ overexpression effects in ERBB2-amplified tumours, we optimised high throughput RNA interference screening procedures in a panel of ERBB2-amplified tumour cell lines (see Methods). In addition to several ERBB2-amplified tumour lines we included a number of non-ERBB2-amplified breast tumour models as controls. In brief, cell lines were reverse transfected with siRNA targeting each gene in a 96-well plate format and cell viability determined 7 days later using Cell TitreGlo (Promega, Madison, WI, USA), which measures cellular ATP. To identify optimal screening conditions, cell number, siRNA concentration and duration of the screen were optimised to obtain (i) o10% reduction in viability in cells transfected with a control, non-targeting siRNA when compared with mock (no siRNA)-transfected cells; (ii) high efficiency of transfection, as defined by 470% loss of viability in cells transfected with siRNA targeting the essential kinase PLK1; and (iii) o90% cell confluency at 7 days post transfection, so as to maximize the possibility of identifying loss of viability effects. As far as was possible, cell lines with similar doubling times (maximum 48 h) were selected for screening so as to minimise the impact of differential proliferation rates across the screen as a whole. Cell lines excluded from further siRNA screening as they failed growth time criteria were SUM190, UACC812 and UACC893.
Following optimisation, each cell line was screened in triplicate using a siRNA library targeting the 369 genes previously identified as amplified/overexpressed in primary ERBB2 þ ve breast cancers and also amplified in at least two ERBB2 þ ve cell lines. The siRNA screening library was composed of one SMARTPool (Dharmacon, Lafayette, CO, USA) per well, where each SMARTPool consisted of four different siRNA species, all targeting the same gene. Cell viability data from each replicate screen was standardized using a Z-score/median absolute deviation approach where negative Z-scores represented cell inhibitory effects caused by siRNA transfection. 26 The quality of each screen was assessed by the performance of non-targeting siRNA (siCON) and siRNA targeting PLK1 with the subsequent calculation of a dynamic range z 027 for each screen (Figures 4a-c) . The extent of replication between triplicate screens was assessed by Spearman's correlation coefficients (r 2 ), and in each case we observed r 2 of 40.7 for each replica comparison, suggesting highly reproducible data. In addition, unsupervised clustering of Z-score data also showed that experimental triplicates for each cell line clustered together with 100% concordance (Figure 4d ). In total, these quality metrics suggested that the effects observed were reproducible and robust, and that we were able to confidently compare viability effects across the panel of cell lines (Supplementary Table S5 ).
Ten ERBB2-amplified cell lines were used in the initial siRNA screen and six non-ERBB2-amplified cell lines were used as controls. Following robust quality control, two ERBB2-amplified cell lines-MDAMB453 and SUM225-were excluded from the analysis as the separation of negative and positive controls as assessed by z 0 was inadequate. A Z-score of p À 2 was used as the threshold for defining significant cell inhibitory effects in each screen, where Zp À 2 is approximately equal to a chance probability, Q, ofo0.02 (1 in 44) in each screen and Q ¼ (0.02) 3 for effects that occurred in all three replica screens. Using this threshold, 128 siRNAs inhibited growth of at least one cell line and 72 siRNAs inhibited at least two cell lines. There were 20 siRNAs that inhibited at least half of the panel. The top hits ranked by Z-score for each cell line are shown in Supplementary Table S6 . As a general observation, we did note that the functional viability profiles of the ERBB2-amplified cell lines were relatively diverse and only 20 siRNAs elicited inhibition in at least half the panel of 14 cell lines. This was perhaps expected, given the relative genetic heterogeneity of ERBB2-amplified primary tumours and cell lines.
Correlation of functional viability profiles with genomic and transcriptomic profiles As proof of principle that our approach could identify genetic dependencies in ERBB2-amplified breast cancer, we integrated genomic, transcriptomic and functional data for the ERBB2 gene itself. Although all ERBB2 þ ve cell lines showed ERBB2 amplification and overexpression, only the viability of three (BT474, SKBR3 Figure 2c) . We also noted that BT474, SKBR3 and ZR75.30 were three of the most lapatinib-sensitive cell lines and that there was a significant correlation between lapatinib SF 50 and survival fraction inhibition by ERBB2 siRNA (Figure 5c ). We investigated whether the cell lines showed similar sensitivity profiles with the more potent pan-HER and irreversible targeting agents BIBW2992 and canertinib. Cell lines that were resistant to lapatinib and also insensitive to ERBB2 siRNA were also resistant to BIBW2992 and canertinib (Figure 5d ). Taken together, these results indicate that a proportion of the ERBB2-amplified and overexpressing breast cancer cell models are not dependent on ERBB2 signalling for their viability, possibly as they have developed alternate pathways that sustain viability and continued proliferation.
To further analyse the pattern of ERBB2 addiction across our cell line panel, we examined sensitivity to silencing of the ERBB2 dimerisation partner ERBB3. 28 Sensitivity to ERBB3 siRNA correlated with both sensitivity to ERBB2 siRNA and also lapatinib sensitivity (Supplementary Figure 3a) . In addition, we noted that three out of four independent siRNAs directed against ERBB3 not only inhibited ERBB3 expression but also induced apoptosis (Supplementary Figure 3b) . These data support the hypothesis that some, but not all ERBB2-amplified cell models, and presumably tumours are addicted to ERBB3-mediated signalling and could be sensitive to dual ERBB2/ERBB3 inhibitors, or a combination of anti-ERBB2 and anti-ERBB3 agents. 28, 29 TFAP2C amplification and overexpression represents a genetic dependency in some ERBB2 þ ve breast cancer cell models Having established proof of principle that the integration of genomic, transcriptional and functional profiling could identify genetic dependencies in ERBB2 þ ve breast cancer, we examined the three data sets to identify additional genes, where sensitivity to siRNA significantly correlated with increases in copy number/ mRNA expression. Given the limited sample size, we could not rule Functional profiling of ERBB2-amplified breast cancer K-K Shiu et al out type II or b errors for the identification of genes that were consistently overexpressed when amplified. To avoid the exclusion of potential drivers solely on statistical grounds, we also searched for recurrently amplified genes whose siRNA silencing caused significant loss of cell viability in at least two cell lines. These genes are shown in Table 1 . Of these genes, TFAP2C was amplified and overexpressed in BT474 and SKBR3 (Supplementary Figure 4a) . TFAP2C amplification and overexpression in these models was confirmed using a CISH probe and a specific antibody to TFAP2C on our cell line microarray (Figure 6c ), as well as by western blot analysis (Supplementary Figure 4b) . We also observed a significant correlation between TFAP2C copy number gain and amplification/overexpression in our tumour cohort (Supplementary Figure 4c) . Furthermore, in our entire 58 ERBB2 þ ve primary breast cancer data set, three tumours exhibited TFAP2C amplification and 26 exhibited TFAP2C copy number gain (www.rock.icr.ac.uk). To eliminate possible off target effects of siRNA, we then repeated the screen with three independent siRNAs to TFAP2C across nine ERBB2-amplified cell lines. We found that these three siRNAs and the original siRNA smart pool significantly inhibited two cell lines BT474 and SKBR3 (Figures 6a  and b ). To validate this finding, we transfected each siRNA duplex into BT474 and SKBR3 cells to establish the gene-silencing effect. Three siRNAs significantly reduced TFAP2C protein levels 72 h following transfection (Figure 6d ). In addition, silencing of TFAP2C caused significant apoptosis as shown by an increase in PARP cleavage ( Figure 6d ) and caspase activity (Supplementary Figure 5) . Taken together, this suggested that TFAP2C when amplified and overexpressed is a potential oncogenic driver when co-amplified with ERBB2, and that its silencing causes cell death via an apoptotic pathway. We also assessed the possibility that the effect of reducing TFAP2C could be caused by affecting ERBB2 expression as previous studies have shown that TFAP2C can bind to promoter regions upstream and downstream of ERBB2 30,31 and affect ERBB2 transcriptional activity. 32 Therefore, we transfected three independent siRNAs that targeted TFAP2C into BT474 and SKBR3 cells. This resulted in decreased ERBB2 protein expression after 72 h (Figure 6d) . However, the expression of ERBB2 cDNA via a heterologous promoter did not ostensibly alter the cell inhibitory or proapoptotic effects of TFAP2C siRNA (Supplementary Figures 5 and 6 ), suggesting that the inhibitory effect of TFAP2C silencing may not entirely be mediated by an effect on ERBB2 levels.
DISCUSSION
In this study, we have assessed the multiple genetic dependencies of ERBB2-amplified breast cancers, using a combination of genomic profiling and parallel functional analysis in multiple breast cancer cell lines. The integration of genomic and transcriptomic profiling in our study highlights the genomic heterogeneity in this breast cancer subtype. Although this genomic heterogeneity might underpin the variable clinical outcomes for patients with this aggressive disease, we reasoned that focussing upon those genes that are recurrently amplified and overexpressed in ERBB2 þ ve breast tumours might be a route to identify additional genes that are critical for the survival of ERBB2 þ ve breast tumour cells. Using this approach of integrated molecular and functional profiling we identified a number of genetic dependencies, most notably an effect involving the transcription factor gene TFAP2C. In models where TFAP2C is amplified and overexpressed, TFAP2C silencing by siRNA causes inhibition of cell growth, most likely by inducing apoptosis (Figure 6d ). The sensitivity of TFAP2C-amplified/overexpressing models to siRNA silencing of this gene and the frequency of TFAP2C amplification/overexpression in ERBB2 þ ve breast cancers Functional profiling of ERBB2-amplified breast cancer K-K Shiu et al suggests that this dependency might also exist in the clinical disease.
In general, our genomic and transcriptomic profiling of ERBB2-amplified breast tumours identified a series of events similar to those described in independent studies. For example, the most prevalent regions of amplification identified here included 8q24, 11q13 and 20q13 as observed elsewhere. 10, 19, 33 Furthermore, the integration of genomic data with transcriptomic profiling identified known driver effects such as amplification and overexpression of ERBB2, MYC, PPM1D and so on. 13, 24, 25 We did, however, note a number of differences between our data and that described in other ERBB2 þ ve breast cancer profiling studies. For example; (i) we identified more recurrent amplicons in ERBB2 þ ve breast cancers than other studies. 10, 19, 33 In our study, we only profiled biopsies with 470% tumour content in order to avoid biases associated with stromal cell/non-neoplastic cell contamination. This approach could have increased the level of sensitivity in terms of detecting recurrent amplicons; (ii) although ERBB2-amplified tumours profiled in this study had a predominantly 'firestorm' genomic pattern, in keeping with previous reports, 17 we observed that those ERBB2-amplified tumours with a 'sawtooth' genomic profile were predominantly ER À ve/ERBB2 þ ve. Sawtooth patterns have been reported to be associated with a basal-like/'triple-negative' phenotype and underlying DNA repair deficiencies 13, 23 rather than ERBB2-amplified tumours. Furthermore, we are currently the only study that has used the genomic and transcriptional aberrations observed in this breast cancer subtype and integrated this with functional profiling via high throughput siRNA screens. These findings emphasize how the genomically heterogeneous ERBB2-amplified breast cancers are even within this phenotypic subgroup, and may explain why patients diagnosed with ERBB2 þ ve breast cancers have differing clinical outcomes despite receiving similar therapies. 6, 7 This is the first study to identify TFAP2C (AP2g) as being essential for cell survival in a subgroup of ERBB2-amplified breast tumour models defined by TFAP2C amplification and overexpression. Previously, a number of observations have linked TFAP2C expression to breast cancer. TFAP2C is a member of a family of five activating enhancer transcription factors (TFAP2A-G) that are essential for normal embryogenesis, as well as being linked to cell proliferation, differentiation and cell survival. 34 TFAP2C is located on 20q13, a region which is copy number gained in B18% of all breast cancers. 35 Retrospective studies have correlated high-level TFAP2C expression with high-grade breast cancers, 34 poorer prognosis in patients with invasive breast cancers and resistance to hormone therapy. 36, 37 This may be partly explained by the fact that it has been shown to have roles in upregulating ER-mediated gene transcription by mediating long range chromatin interactions 38 and to act as repressor of transcription by inhibiting CDKN1A, a growth inhibitor. 39 Here we expand these observations and demonstrate that TFAP2C amplification is significantly enriched in patients with ERBB2 þ ve breast cancer (29/58, 50%) and that amplification also correlates with TFAP2C mRNA overexpression (Supplementary Figure 4a) . TFAP2C has been shown to bind at multiple promoter sites proximal and distal of the ERBB2 gene, 30, 31, 40 suggesting a mechanism by which TFAP2C could modulate ERBB2 signalling. Indeed, we show here that in ERBB2 þ ve models that are inhibited by TFPA2C siRNA, ERBB2 protein levels are suppressed by TFAP2C silencing (Figure 6d ). However, as transcription factors are rarely specific for single genes, we cannot discount the possibility that the dependency upon TFAP2C that we observe is also mediated by modulating the expression of a number of genes. 34, 38 We do note that the expression of ERBB2 cDNA from a heterologous promoter did not reverse the cell inhibitory effect of TFAP2C siRNA (Supplementary Figure 6) . Notwithstanding the difficulties in replicating physiological expression of genes with cDNA expression constructs, it seems possible that this result is in keeping with the hypothesis that the dependency on TFAP2C is explained by the activity of this transcription factor on a number of genes in addition to ERBB2.
In addition to identifying TFAP2C as a genetic dependency in ERBB2 þ ve breast cancer, a comparative analysis of anti-ERBB drug sensitivity and ERBB2 siRNA sensitivity in ERBB2 þ ve breast cancer models confirms that only a small fraction of the ERBB2-amplified breast cancer lines are truly addicted to the ERBB2 oncogene. [41] [42] [43] For example, we have shown that ERBB2 þ ve tumour cell line models that are resistant to multiple ERBB2 and pan-ERB-targeted agents are also resistant to ERBB2 silencing by siRNA (Figure 5c ). Although multiple potential mechanisms of acquired and de novo resistance to ERBB2-targeted therapies have been previously proposed, 42, [44] [45] [46] [47] few have been validated in prospective clinical trials. 47 Our data indicate that one fundamental reason for de novo resistance to ERBB2-targeted agents is the loss of dependency on the ERBB2 pathway, as opposed to a pharmacological mechanism, such as increased drug efflux or metabolism that could impair the ability of a drug to inhibit its target. The clinical implication of these data would be that for some patients, the failure to respond to an ERBB2-targeted agent such as lapatinib would also predict a poor response to other ERBB2-targeted therapies. We also demonstrate that ERBB3 represents a genetic dependency in a subset of ERBB2-amplified models, supporting the focus upon this ERBB2 dimer partner as an additional therapeutic target. 28, 48 Our comparative anti-ERB drug/ ERBB2 siRNA data indicate, however, that such therapy may only be particularly effective in ERBB2 þ ve cancers that remain addicted to ERBB2. Our study also highlights the fact that, in general, the functional dependencies in ERBB2 þ ve breast tumour models are relatively diverse and that many of the dependencies identified are isolated to a relatively small number of models. It seems unlikely that this is an artefact of the RNAi screening approach used (for example, the effect of ERBB2 siRNA mirrors the effect of anti-ERB drugs, giving some confidence in the validity of the RNAi functional profiling) but perhaps is more reflective of the inherent genetic and functional heterogeneity of both the models and the tumours profiled.
In conclusion, we propose that TFAP2C amplification and overexpression represents a genetic dependency in ERBB2 þ ve breast cancer. Integration of molecular and functional profiling in ERBB2 þ ve breast cancer identifies genes that warrant further study. One particular area of focus in the future will be to correlate the expression and copy number genes such as TFAP2C in tumour biopsy material obtained from large neoadjuvant-targeted therapy trials involving anti-ERBB2-targeted agents as these become available.
MATERIALS AND METHODS
Patient tumour samples
Fifty-eight fresh frozen ERBB2 þ ve breast cancer samples were obtained after approval by local Ethics Committees from the authors' institutions. All tumours were either ERBB2 2 þ or 3 þ on immunohistochemistry and were confirmed to be amplified with CISH and/or aCGH. All patients had stage I-III disease, and samples received were from the primary surgery. None of the tumours had received neoadjuvant therapy. Their clinicopathological characteristics are shown in Supplementary Table S1. All tumours possessed 470% neoplastic cell content and had matching RNA of sufficient quality for expression arrays. DNA and RNA were extracted as previously described. 13, 49, 50 ER and progesterone receptor status was determined by immunohistochemical analysis using the 6F11 (1:150) and PgR636 (1:200) antibodies, respectively, as previously described. 13, 22 The Allred scoring system was employed and tumours were considered positive when the score was X3. HER2 gene amplification was defined based on CISH analysis using an US Food and Drug Administrator approved probe (SpotLight HER2 amplification probe, Invitrogen, Carlsbad, CA, USA) and/ or by inspection of the results of aCGH analysis, as previously described. 9 Cancer cell lines Fourteen commercially available cell lines known to harbour ERBB2 gene amplification and 9 non-ERBB2-amplified controls representing the other molecular subtypes of breast cancer were selected. They were purchased from ATCC (Manassas, VI, USA) unless otherwise stated, and were maintained as per source recommendations. These included CAL51, CAMA1, HCC1143, MCF7, MDAMB468, MDAMB231, MCF12A, SUM149 (Asterand), T47D, BT474, HCC202, HCC1569, HCC1954, MDA-MB-361, MDA-MB-453, SKBR3, UACC-812, UACC-893, ZR-75.30, SUM190PT (Asterand) SUM225CWN (Asterand), JIMT-1 (DSMZ) and VP229 (EACC). DNA was extracted and purified using DNeasy (Qiagen Ltd, Crawley, West Sussex, UK) total DNA purification protocol for cultured animal cells, and quantified using Pico Green. DNA was then stored at À 20 1C before use. Total RNA Functional profiling of ERBB2-amplified breast cancer K-K Shiu et al was extracted in a RNase-free environment using TRIzol (Invitrogen) standard manufacturer's protocol (Cat No 15596-018). RNA pellets were airdried and resuspended in a total volume of 50 ml nuclease-free water (Ambion, Paisley, UK). RNA quality and quantity were assessed by using an Eukaryote Total RNA Nano Series II Chip with an Agilent 2100 Bioanalyser (Winnersh, UK) according to the manufacturer's instructions, then stored at À 80 1C before use. We used short tandem repeat profiling to verify authenticity of the panel of cell lines. We simultaneously amplified eight short tandem repeat loci, in a multiplex PCR reaction (Promega PowerPlex 1.2 System) and used the ATCC and DMSZ databases for comparison, where possible. In addition, gain and loss of expression of particular subtype markers, described by Hollestelle et al. 51 were confirmed by western blot as well as microarray analysis.
Microarray comparative genomic hybridization and gene expression profiling All cell line and tumours were subjected to aCGH (Breakthrough Breast Cancer Research Centre) 32K BAC array platform and profiled as previously described. 23 All cell lines and 45 tumours were subjected to mRNA gene expression profiling. In brief expression profiling data of cases from the NKI were generated as previously described 22 using the Human Genome Oligo Set Version 3.0 arrays, which contains 34 580 probes representing 24 650 genes. These arrays were obtained from the central microarray facility at the NKI. Detailed information on the array platform and hybridization protocols can be found at http://microarrays.nki.nl. The RNA from the 14 Centro Nacional de Investigaciones Oncoló gicas (CNIO) tumours and all cell lines was processed using the Illumina Human Ref6 Chip v2, as per the manufacturer's protocol (www.illumina.com). Fluorescent intensities were normalized through Bead Studio, and processed using Lumi package in R as previously described. 20 Before data analysis the gene lists for the NKI and CNIO cohorts were mapped to the human genome (ensembl HG18 assembly 49). Genes with missing values or ambiguous mapping information were excluded. Probes with 475% flagged values were removed. This left 17 490 and 12 235 unambiguously mapped unique genes with known Ensembl identities for analysis in the NKI and CNIO cohorts, respectively. Correlation of gene expression and aCGH data are described previously. 23, 52 Data acquisition and analysis were fully Minimal Information About a Microarray Experiment (MIAME) compliant. For the CNIO cohort, gene expression data are publicly available at ArrayExpress http://www.ebi.ac.uk/microarray-as/ae/ (accession number: E-TABM-543). For details of the NKI cohort, see Turner et al. Correlation of siRNA Z-score with gene expression and aCGH data
The correlation between siRNA Z-score and normalized gene expression was examined for genes where siRNA caused significant loss of viability (Zo À 2). Z-score was compared with normalized gene expression using Pearson correlation coefficient. A gene was taken as being significantly correlated if the Pearson correlation coefficient was significantly different to the null hypothesis (Po0.05), the correlation was inverse, and the variation in gene expression between cells lines were significantly different as assessed by one-way analysis of variance. The number of cases harbouring amplifications, gains losses and deletions which also corresponded with Z-score hits in the same cell line was also calculated as previously described. 52 Immunoblotting Protein lysates were prepared using RIPA lysis buffer (50 nM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 0.1% deoxycholic acid (DOC), 1% TritonX-100, 50 mM NaF, 1 mM Na3VO4and protease inhibitors). Protein concentrations were measured using BioRad Protein Assay Reagent (BioRad, Hemel Hempstead, UK). Antibodies targeting the following were used as per manufacturer's instructions: Actin, TFAP2C sc-12763 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Cleaved PARP 19F4, ERBB2 29D8, ERBB3 1B2 (Cell Signalling, Danvers, MA, USA). All secondary antibodies used for western blot analysis were horseradish peroxidase-conjugated. Protein bands were visualised using ECL (GE Healthcare, Cardiff, UK) and MR or XAR film (Kodak).
Validation of gene silencing by siRNA
Validation of RNAi gene silencing was determined by western blotting and by viability assays of silencing effects with individual siRNA duplexes (siGENOME, Dharmacon). Protein lysates were collected 48-72 h following transfection of individual siRNA for western blot analysis. Individual siRNA sequences that were on target for TFAP2C were 5 0 -GUAAACCAGUGGCAGAAUA-3 0 , 5 0 -CGACAUGCCUCACCAGAUG-3 0 , 5 0 -ACACU GGAGUCGCCGAAUA-3 0 , for ERBB2 were; 5 0 -GGACGAAUUCUGCACAAUG-3 0 , 5 0 -CUACAACACAGACACGUUU-3 0 , 5 0 -AGACGAAGCAUACGUGAUG-3 0 , for ERBB3 were: 5 0 -GCAGUGGAUUCGAGAAGUG-3 0 , 5 0 -AGAUUGUGCUCACGG GACA-3 0 , 5 0 -GUGGAUUCGAGAAGUGACA-3 0 and 5 0 -GCGAUGCUGAGAACC AAUA-3 0 . All siRNA identities are available via the Dharmacon website (http://www.dharmacon.com).
Survival assays
For measurement of sensitivity to lapatinib, canertinib and BIBW2992 treatment, cells were plated in 96-well plates and exposed to the drug at the indicated concentrations. Cells were dosed at 24 and 96 h. After 7 days, cell viability was measured using CellTiter Glo Luminescent Cell Viability Assay (Promega). Surviving fractions were calculated and drug sensitivity curves plotted as previously described using Prism. 53 Caspase activity assay
The ApoTox Glo triplex assay (Promega) was used to assess caspase 3/7 activity and viability as per the manufacturer's instructions. Cells were reverse transfected with siRNA (Dharmacon) using Lipofectamine 2000 (Invitrogen). Cells were plated in 96-well plates at a density of 20 000 cells per well. Twenty-four, and 96 h post transfection, caspase 3/7 activity and viability effects were assessed, respectively.
Immunohistochemistry
Cell line microarray blocks containing three representative replicate cores from each cell line were prepared, cut and subjected to immunohistochemical analysis with antibodies against ER, progesterone receptor, ERBB2, EGFR, and TFAP2C. All markers were scored by JR-F blinded to the identity of the samples.
Chromogenic in situ hybridization
The CISH probe for TFAP2C was constructed and optimized on the cell line microarray as previously described. 54 RPCI tiling path clones were purchased from Source Bioscience: RP5-897D18, RP5-843L14 and RP4-539E24.
Statistical analysis
Statistical analysis of aCGH and gene expression data was performed with Excel and GraphPad Prism version 5.01 (GraphPad Software, La Jolla, CA, USA).
